Sugi Predict

Sugi Predict / Compounds / SCHEMBL6960198

SCHEMBL6960198

SCHEMBL6960198

COC(=O)/C=C/c1ccc(F)c(F)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 1/20 0.63
▸ APP P05067 1/20 0.63
▸ PTPN1 P18031 1/20 0.59
▸ CA12 O43570 2/20 0.59
▸ CA1 P00915 2/20 0.59
▸ CA2 P00918 2/20 0.59
▸ CA9 Q16790 2/20 0.59
▸ TYR P14679 1/20 0.59
▸ CA7 P43166 1/20 0.59
▸ CA14 Q9ULX7 1/20 0.59
▸ EPHX2 P34913 1/20 0.58
▸ KDM4E B2RXH2 3/20 0.56
▸ ALDH1A1 P00352 3/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ MAPT P10636 2/20 0.56
▸ JAK2 O60674 1/20 0.56
▸ GAA P10253 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ FDPS P14324 1/20 0.54
▸ PTGS2 P35354 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31560386 1.00 TTR (0.63) TTRAPPPTPN1CA12CA1
SCHEMBL6960203 1.00 TTR (0.63) TTRAPPPTPN1CA12CA1
SCHEMBL2085779 0.87 TTR (0.73) TTRAPPPTPN1CA12CA1
SCHEMBL13934474 0.87 TTR (0.73) TTRAPPPTPN1CA12CA1
SCHEMBL14926722 0.87 TTR (0.59) TTRAPPPTPN1CA12CA1
SCHEMBL7787485 0.87 TTR (0.59) TTRAPPPTPN1CA12CA1
SCHEMBL2847487 0.87 TTR (0.59) TTRAPPPTPN1CA12CA1
SCHEMBL2847488 0.87 TTR (0.59) TTRAPPPTPN1CA12CA1
SCHEMBL6821280 0.85 EPHX2 (0.66) TTRAPPPTPN1CA12CA1
SCHEMBL1893825 0.85 TTR (0.58) TTRAPPPTPN1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025045746-A1 PYRAZOLE DERIVATIVES AS SARM1 INHIBITORS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2025-03-06 — — WO disclosed
EP-3330256-B1 HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY SHIONOGI & CO (JP) 2021-06-16 — — EP disclosed
US-10640495-B2 Heterocycle derivatives having TrkA inhibitory activity SHIONOGI & CO., LTD. (JP) 2020-05-05 — — US disclosed
US-20180201607-A1 HETEROCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2018-07-19 — — US disclosed
EP-3330256-A1 HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2018-06-06 — — EP disclosed
WO-2013144295-A1 SYNTHESIS OF 2-(3,4-DIFLUOROPHENYL)CYCLOPROPANAMINE DERIVATIVES AND SALTS SANDOZ AG (CH) 2013-10-03 — — WO disclosed
WO-2013144295-A1 SYNTHESIS OF 2-(3,4-DIFLUOROPHENYL)CYCLOPROPANAMINE DERIVATIVES AND SALTS SANDOZ AG (CH) 2013-10-03 — — WO disclosed
EP-2644590-A1 Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts LEK Pharmaceuticals d.d. (SI) 2013-10-02 — — EP disclosed
EP-2644590-A1 Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts LEK Pharmaceuticals d.d. (SI) 2013-10-02 — — EP disclosed
EP-0998285-A4 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2003-01-08 — — EP disclosed
EP-1019052-A4 ALPHA 1A ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2001-05-16 — — EP disclosed
US-6228870-B1 BENIGN PROSTATIC HYPERPLASIA; REDUCTION OF HYPOTENSION SIDE EFFECT MERCK & CO., INC. 2001-05-08 — — US disclosed
US-6143750-A NITROGEN HETEROCYCLIC COMPOUNDS AS ENZYME INHIBITORS, FOR PROSTATE PROBLEMS AND MUSCLE RELAXANTS MERCK & CO., INC. (US) 2000-11-07 — — US disclosed
EP-1019052-A1 ALPHA 1A ADRENERGIC RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2000-07-19 — — EP disclosed
WO-2000027827-A1 OXAZOLIDINONES USEFUL AS ALPHA 1A ADRENOCEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2000-05-18 — — WO disclosed
WO-2000027817-A1 OXAZOLIDINONES USEFUL AS ALPHA 1A ADRENOCEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2000-05-18 — — WO disclosed
EP-0998285-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2000-05-10 — — EP disclosed
US-6037354-A ADMINISTERING PHENYL-SUBSTITUTED THIAZOLIDIN-4-ONE OR OXAZOLIDIN-2-ONE DERIVATIVE TO TREAT BENIGN PROSTATE HYPERPLASIA; SIDE EFFECT REDUCTION MERCK & CO., INC. (US) 2000-03-14 — — US disclosed
WO-1998057640-A1 ALPHA 1A ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1998-12-23 — — WO disclosed
WO-1998057641-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1998-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10640495-B2 Heterocycle derivatives having TrkA inhibitory activity NTRK2, NR5A2, NTRK1 TTR 3174/4885APP 3234/4885PTPN1 350/4885
US-20180201607-A1 HETEROCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY NTRK2, NR5A2, NTRK1 TTR 3174/4885APP 3234/4885PTPN1 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.